XRP2 Stock Overview
A biotechnology company, engages in the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Silence Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.16 |
| 52 Week High | US$21.40 |
| 52 Week Low | US$3.16 |
| Beta | 1.07 |
| 1 Month Change | -30.09% |
| 3 Month Change | -52.12% |
| 1 Year Change | -83.63% |
| 3 Year Change | -81.63% |
| 5 Year Change | n/a |
| Change since IPO | -80.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| XRP2 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.0% | 0.4% | -1.3% |
| 1Y | -83.6% | -14.3% | 13.1% |
Return vs Industry: XRP2 underperformed the German Biotechs industry which returned -12.7% over the past year.
Return vs Market: XRP2 underperformed the German Market which returned 13.3% over the past year.
Price Volatility
| XRP2 volatility | |
|---|---|
| XRP2 Average Weekly Movement | 13.1% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.1% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: XRP2's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: XRP2's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 116 | Craig Tooman | www.silence-therapeutics.com |
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs.
Silence Therapeutics plc Fundamentals Summary
| XRP2 fundamental statistics | |
|---|---|
| Market cap | €155.39m |
| Earnings (TTM) | -€41.88m |
| Revenue (TTM) | €39.98m |
3.9x
P/S Ratio-3.7x
P/E RatioIs XRP2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XRP2 income statement (TTM) | |
|---|---|
| Revenue | US$43.26m |
| Cost of Revenue | US$11.81m |
| Gross Profit | US$31.45m |
| Other Expenses | US$76.76m |
| Earnings | -US$45.31m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.96 |
| Gross Margin | 72.70% |
| Net Profit Margin | -104.74% |
| Debt/Equity Ratio | 0% |
How did XRP2 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/24 02:44 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Silence Therapeutics plc is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | BMO Capital Markets Equity Research |
| Konstantinos Biliouris | BMO Capital Markets Equity Research |
| Thomas Shrader | BTIG |